J0609 Ferric Citrate HCPCS Reimbursement

HCPCS Level II code J0609 denotes oral ferric citrate (3 mg ferric iron) used for patients with end-stage renal disease (ESRD) undergoing dialysis. The code identifies a specialized oral pharmacologic therapy intended to manage iron and phosphate parameters in dialysis-dependent patients and is relevant to dialysis centers, outpatient clinics, and pharmacy dispensing processes nationwide. Nationally, coverage and utilization of this medication affect medication management, anemia control, and phosphate binding strategies in the ESRD population.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for use in dialysis-dependent ESRD, typical sites of service, and what to expect in billing workflows. The publication summarizes payer coverage patterns, reimbursement considerations, and benchmark metrics where available, and highlights relevant policy updates that influence access and coding practices for oral ferric citrate in dialysis settings.

The content provides actionable reference material for revenue cycle and clinical teams seeking concise information on HCPCS Level II code J0609, including code definition, service context, payer coverage scope, and areas where institutional policies and payer rules commonly intersect. Data not available in the input are noted where applicable.

Billing Code Overview

HCPCS Level II code J0609 represents ferric citrate, oral, 3 mg ferric iron (for ESRD on dialysis). This code covers the provision of an oral iron phosphate binder formulation specifically indicated for patients with end-stage renal disease (ESRD) receiving dialysis.

Service type: Oral medication (pharmacologic therapy) intended for management of iron and phosphate balance in dialysis-dependent ESRD patients.

Typical site of service: Outpatient dialysis centers and clinic-based infusion/medication dispensing areas associated with dialysis care, as well as pharmacy dispensing for patients on dialysis.

Clinical Context

A typical patient is an adult with end-stage renal disease (ESRD) on maintenance hemodialysis who requires oral iron replacement to manage iron deficiency anemia related to chronic kidney disease and ongoing dialysis blood losses. The medication J0609 (ferric citrate, oral, 3 mg ferric iron) is provided through the dialysis unit or an affiliated clinic pharmacy and is documented as a billable HCPCS Level II drug when dispensed for ESRD patients receiving dialysis.

Clinical workflow: the nephrology team documents anemia parameters (hemoglobin, transferrin saturation, ferritin) and determines need for iron therapy. The dialysis nurse or clinic pharmacist dispenses J0609 per the nephrologist’s order; administration is usually oral self-administration by the patient at home or during dialysis treatments if supported. Medication reconciliation, counseling on dosing and adverse effects, and monitoring labs within 4–12 weeks are completed. Billing occurs under the patient’s ESRD treatment claims using the HCPCS code J0609 with appropriate modifiers reflecting service circumstances and payer requirements.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier

Taxonomy Code	Specialty	Notes
207RC0000X	Nephrology	Primary specialty managing ESRD and prescribing `J0609`.
363LP0800X	Dialysis Facility	Facility taxonomy for providers and clinics that dispense and bill dialysis-related medications.
207Q00000X	Internal Medicine	Hospital-based or clinic internists who co-manage anemia in CKD/ESRD patients.
363LF0000X	Pharmacist	Clinic or dialysis pharmacists responsible for dispensing, counseling, and medication management.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`N18.6`	End stage renal disease	Primary indication for use of `J0609` in patients on maintenance dialysis.
`D63.1`	Anemia in chronic kidney disease	Direct clinical diagnosis indicating need for iron supplementation and anemia management.
`N18.9`	Chronic kidney disease, unspecified	General CKD diagnosis relevant to iron deficiency and anemia workup when ESRD status is not explicitly coded.
`E83.11`	Iron deficiency anemia due to blood loss (chronic)	Identifies iron deficiency as the cause of anemia and supports need for iron therapy.
`E83.0`	Iron deficiency anemia, unspecified	Common anemia diagnosis used when iron deficiency is documented but etiology is not fully specified.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`82565`	Urine occult blood, by peroxidase activity; qualitative	Used when evaluating iron deficiency causes such as gastrointestinal blood loss during diagnostic workup prior to initiating iron therapy.
`82728`	Iron; total, serum	Baseline and follow-up laboratory test used to monitor iron status before and during ferric citrate therapy.
`85018`	Blood count; hemoglobin determination	Point-of-care or laboratory hemoglobin measurement to assess anemia severity and response to therapy.
`84443`	Thyroid stimulating hormone (TSH)	Screening test performed in anemia workup to exclude endocrine causes that may affect anemia management.
`36415`	Collection of venous blood by venipuncture	Routine phlebotomy code used when obtaining labs to guide ferric citrate therapy.

OpenPayer

Summary & Overview

HCPCS J0609: Ferric Citrate Oral for ESRD on Dialysis